Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator

1. A method of treating a subject suffering from a myeloproliferative neoplasm which comprises administering to the subject an amount of a Lyn kinase activator effective to activate Lyn kinase so as to thereby treat the subject.

2. The method of claim 1 , wherein the myeloproliferative neoplasm is essential thrombocytosis (ET) or primary myelofibrosis (MF).

3. The method of claim 1 , wherein the subject's chromosomes comprise a JAK2 mutation.

4. The method of claim 3 , further comprising administering a JAK2 inhibitor to the subject.

5. The method of claim 1 , wherein the Lyn kinase activator is a compound having the structure:

wherein

X is O, S or NH;

Y is O, S, CH 2 or NH;

Z is aryl or heteroaryl;

R 1 is —H or alkyl;

Each of R 2 and R 3 is independently —H, —CF 3 , —CN, —NO 2 , —OR 4 , CO 2 R 4 , —CO 2 R 4 , —NHR 4 , —NR 4 R 4 , alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, or halogen, and

wherein each R 4 is independently —H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, or heteroaryl,

or a pharmaceutically acceptable salt or ester thereof.

6. The method of claim 5 ,

wherein Z is phenyl, pyridine, or pyrimidine, unsubstituted or substituted,

or a pharmaceutically acceptable salt or ester thereof.

7. The method of claim 6 , wherein Z is a compound having the structure:

wherein each of R 5 , R 6 , R 7 , R 8 and R 9 is independently —H, —CF 3 , —CN, —NO 2 , —OR 10 , CO 2 R 10 , —CO 2 R 10 , —NHR 10 , —NR 10 R 10 , alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, or halogen, and

wherein each R 10 is independently —H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, or heteroaryl,

or a pharmaceutically acceptable salt or ester thereof.

8. The method of claim 7 , wherein Z is a compound having the structure:

wherein each of R 5 , R 6 , R 7 , R 8 and R 9 is —H, —CH 3 ,—Cl, —F, —OH, —CF 3 , or —NH 2 ,

or a pharmaceutically acceptable salt or ester thereof.

9. The method of claim 8 , wherein Z is

or a pharmaceutically acceptable salt or ester thereof.

10. The method of claim 5 , wherein each of X and Y is O,

or a pharmaceutically acceptable salt or ester thereof.

11. The method of claim 5 , wherein each of R 1 , R 2 and R 3 is —H,

or a pharmaceutically acceptable salt or ester thereof.

12. The method of claim 5 , wherein the Lyn kinase activator is a compound having the structure:

or a pharmaceutically acceptable salt or ester thereof.

13. The method of claim 5 , wherein the Lyn kinase activator is a compound having the structure:

or a pharmaceutically acceptable salt or ester thereof.

14. A method of treating a subject suffering from a myeloproliferative neoplasm which comprises administering to the subject an effective amount of a composition comprising a compound having the structure:

wherein

X is O, S or NH;

Y is O, S, CH 2 or NH;

Z is aryl or heteroaryl;

R 1 is —H or alkyl;

Each of R 2 and R 3 is independently —H, —CF 3 , —CN, —NO 2 ,—OR 4 ,

CO 2 R 4 ,—CO 2 R 4 ,—NHR 4 , —NR 4 R 4 , alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heteroaryl, or halogen, and

wherein each R 4 is independently —H, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, or heteroaryl,

or a pharmaceutically acceptable salt or ester thereof, in an amount effective to activate Lyn kinase.

15. The method of claim 14 , wherein the compound has the structure:

or a pharmaceutically acceptable salt or ester thereof.